Department of Pathology, Faculty of Medicine, Cairo University, Egypt.
Department of Pathology, Faculty of Medicine, Beni-Suef University, Egypt.
Asian Pac J Cancer Prev. 2021 Dec 1;22(12):3921-3925. doi: 10.31557/APJCP.2021.22.12.3921.
Breast cancer is the most commonly diagnosed female cancer and is a major cause of cancer-related deaths in women. Triple-negative breast cancer (TNBC) is defined as ER, PR and HER2 negative, which are characterized by rapid progression with low survival rates with limited therapeutic choices. Polo-like kinase 1 protein acts as a cell division regulator which is highly expressed in many tumors making it a potentially valuable target for antiproliferative therapies. In this study we tried to evaluate the value of this marker as a possible therapeutic target in TNBC.
This research studied the immunohistochemical expression of PLK1 done on 49 paraffin blocks of TNBC female patients and then correlated with the different clinicopathological parameters.
Our results showed high PLK1 expression in 91.9% of cases. Most of the high grade tumors showed high PLK1 high score (76.9%). All cases showing lymph node metastasis showed high PLK1 expression, implying a statistically significant correlation between PLK1 expression and tumor grade as well as N stage.
PLK1, although a negative prognostic factor, but is a promising therapeutic target for treating TNBC patients.
乳腺癌是最常见的女性癌症，也是女性癌症相关死亡的主要原因。三阴性乳腺癌（TNBC）定义为 ER、PR 和 HER2 阴性，其特征是进展迅速，生存率低，治疗选择有限。Polo 样激酶 1 蛋白作为细胞分裂调节剂，在许多肿瘤中高度表达，使其成为抗增殖治疗的潜在有价值靶点。在这项研究中，我们试图评估该标志物作为 TNBC 可能的治疗靶点的价值。
本研究对 49 例 TNBC 女性患者的 49 个石蜡块进行了 PLK1 的免疫组织化学表达研究，并与不同的临床病理参数相关联。
我们的结果显示，91.9%的病例中 PLK1 表达较高。大多数高级别肿瘤显示 PLK1 高评分（76.9%）。所有显示淋巴结转移的病例均显示 PLK1 表达较高，表明 PLK1 表达与肿瘤分级和 N 分期之间存在统计学显著相关性。
PLK1 虽然是一个负预后因素，但作为治疗 TNBC 患者的有希望的治疗靶点。
